Item 7.01. Regulation FD Disclosure.

Reference is made to the disclosure set forth below in Item 8.01 of this Current Report on Form 8-K which is incorporated herein by reference.



On January 27, 2023, Senti Biosciences, Inc., (the "Company") issued a press
release (the "Press Release") titled, "Senti Bio Announces Pipeline
Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway
Guidance," a copy of which is furnished herewith as Exhibit 99.1. The
information in this Item 7.01 of Form 8-K and Exhibit 99.1 attached hereto is
furnished and shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 (the "Securities
Act"), as amended or the Exchange Act. The information in this Item 7.01 of this
Current Report on Form 8-K will not be deemed an admission as to the materiality
of any information that is required to be disclosed solely by Regulation FD.


Item 8.01.  Other Events.

On January 27, 2023, the Company announced a strategic plan to focus internal
resources on SENTI-202, SENTI-401 and, with potential partners, to develop Gene
Circuits for other programs. The Company also announced that it does not intend
to devote its own resources to the development of SENTI-301A for the treatment
of hepatocellular carcinoma at this time, and is actively pursuing strategic
geographic partnerships for further clinical development of SENTI-301A. This
business realignment will streamline internal efforts and is expected to extend
the Company's cash runway through at least the first quarter of 2024. In
connection with this announcement, the Company has also updated certain
corporate information in a presentation slide deck. A copy of this corporate
presentation is filed herewith as Exhibit 99.2 to this Current Report on Form
8-K and incorporated by reference herein.

Cautionary Statement



This filing and the exhibits include "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended (the
"Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"). We intend these forward-looking statements to be
covered by the safe harbor provisions for forward-looking statements contained
in Section 27A of the Securities Act and Section 21E of the Exchange Act, and
are making this statement for purposes of complying with those safe harbor
provisions. These forward-looking statements reflect our current views about our
plans, intentions, expectations, strategies, and prospects, which are based on
the information currently available to us and on assumptions we have made.
Important factors that may cause actual results to differ materially from those
described in the forward-looking statements are disclosed in the respective
exhibits and in the "Risk Factors" contained in the Company's Form 10-Q filed
with the Securities and Exchange Commission (the "Commission") on November 10,
2022, and other filings we make with the Commission. All forward-looking
statements are expressly qualified in their entirety by such factors. We do not
undertake any duty to update any forward-looking statement except as required by
law.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits

    Exhibit No.                                            Description
        99.1                 Press Release, dated as of January     27,     2023
        99.2                 Corporate presentation
        104                Cover Page Interactive Data File (embedded

within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses